News
Cloudbreak Pharma’s Global Innovative Ophthalmic Pipeline CBT-001 Completes the Enrollment of All Patients in the International Multi-Center Phase III Clinical Trial
Cloudbreak Pharma Inc. is pleased to announce that our pipeline CBT-001, the global innovative ophthalmic drug for the treatment of pterygium has recently completed the
Cloudbreak Pharma Inc.’s CBT-004 indicated for the treatment of vascularised pinguecula has completed Phase II clinical trials in the United States
Cloudbreak Pharma Inc.’s CBT-004 indicated for the treatment of vascularised pinguecula has completed Phase II clinical trials in the United States Cloudbreak Pharma Inc. has
Santen and Cloudbreak execute a new licensing agreement for CBT-001, a topical treatment of pterygium
Santen and Cloudbreak execute a new licensing agreement for CBT-001, a topical treatment of pterygium 6 August 2024 – Osaka, Japan – Santen Pharmaceutical
CBT-004 has completed the first patient-in for Phase 2 clinical trials in the US
We are proud to announce that CBT-004, a potential first-in-class drug for vascularised pinguecula, has completed the first patient-in for Phase 2 clinical trials in
Remarkable Progress in Clinical Trials: CBT-009 and CBT-004
We are proud to announce that CBT-009, our novel ophthalmic formulation of atropine indicated for the treatment of juvenile myopia, has reached agreement with FDA
Seeing Life Better Through Medicine
Imagine a world where everyone can experience the joy and beauty of clear vision. At Cloudbreak, our mission is centered around the belief that vision
